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SUMMARY 
This studv reports the results of an open trial of Sodium Valproate in tardive-dyskinesia. Fifteen patients 
identified having tardive dyskinesia by two psychiatrists independently were treated with Sodium Valproate in dos-
age of 1200 mg/day for 4 weeks. Assessments were made on abbreviated Dyskinesia Scale. There was statistically 
significant improvement after 2 and 4 weeks of treatment. Authors found Sodium Valproate quite effective in the 
management of tardive-dyskinesia. 
Introduction 
Neuroleptic therapy is associated with a 
number of complications which may ap-
pear in the beginning or after years of treat-
ment. Tardive-dyskinesia is one of the im-
portant and most distressing complications 
of neuroleptic therapy. Initially considered 
to be a rare entity, a number of prevalence 
studies have demonstrated that it is relati-
vely common condition. Many treatment 
strategies have been tried for it but none is 
satisfactory. 
In its typical form tardive dyskinesia is # 
seen after long term neuroleptic therapy as 
is suggested by its name i.e. tardive, but it 
may appear as early as 3-6 months of treat-
ment with neuroleptics (Tarsy 1984). 
Tardive dyskinesia is characterised by 
abnormal involuntary movements of orofa-
cial region, extremities and trunk. The most 
common presentation is of bucco-linguo-
masticatory triad which consists of sucking 
and smacking movements of lips, lateral 
jaw movements, puffing of cheeks, thurst-
ing, rolling or fly catching movements of 
tongue and chewing movements etc. This 
bucco-linguo-masticatory triad is some-
times accompanied by choreo-athetoid mo-
vements of limbs and trunk, axial hyperkin-
esis, ballistic movements, rhythmic and 
swaying movements of body from side to 
side and akathisia. All these features toge-
ther are seldom present in a patient at a par-
ticular time and all of these involuntary 
movements disappear during sleep. 
The prevalence of tardive dyskinesia 
among chronically ill psychiatric inpatients 
has shown an increase from 1960 through 
1980. Various studies of prevalence of tar-
dive dyskinesia in chronically ill psychiatric 
inpatients have shown prevalence varying 
from 2.9-42.4 %, the weighted mean pre-
valence being 17.5%. The prevalence of 
tardive dyskinesia in psychiatric outpa-
tients on long term neuroleptic thera-
py varies from 0 to 34.4 % in different stu-
dies fjeste and Wyatt 1981). 
The underlying biochemical distur-
bance in tardive dyskinesia is a state of rela-
tive dopaminergic overactivity. Chronic-
blockade of dopaminergic receptors leads 
to denervation supersensitivity (Burt et al 
1977). Another mechanism that can lead to 
dopaminegic overactivity is the impair-
ment of other modulating systems that in-
teract with dopamine mechanisms in basal 
ganglia. It is possible that damage to the 
striatal interncurons that regulate activity 
of dopamine neurons by feedback mecha-
nisms using acetylcholine, gamma amino 
butyric acid (GABA) or peptides as neuro-
transmitters leads to tardive-dyskinesia 
(Tarsy 1984). Based on the above men-
tioned mechanism, a number of drugs have 
been used in tardive dyskinesia varying 
from dopamine antagonists to dopaminergic 
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drugs through cholinergic, GABA ergic 
and anticholinergic drugs, noradrenergic 
blockers and neuroleptic withdrawl 
(Jeste apd Wyatt 1982, Simpson et al 
1982). Till now there is no satisfactory 
treatment for tardive-dyskinesia. Neuro-
leptic withdrawal reverses dyskinesia in* 
37% of cases, rest of cases belonging to 
persistent tardive dyskinesia (Jeste and 
Wyatt 1982). In two excellent reviews on 
the treatment of tardive dyskinesia, Jeste 
and Wyatt (1982) and Simpson et al 
(1982) opine that neuroleptics are supe-
rior to all other drugs in suppressing tar-
dive dyskinesia, while among non neuro-
leptic drugs GABA-ergic drugs aid puta-
tive nor-adrenergic blockers appear to be 
promising at this time. Among putative 
nor-adrenergic blockers, clonidine was 
reported to suppress psychotic and dyski-
netit symptoms in two patients with tar-
dive dyskinesia (Freedman et al 1980). 
However, this needs further investiga-
tion. Propranolol, a beta-adrenergic blo-
cker 'has also been found to be useful in 
suppressing tardive dyskinesia (Bacher 
and Lewis 1980, Kulik and Wilbur 1980). 
Amongst GABA-ergic agents-benzo-. 
diazepines and Sodium Valproate have 
beerf tried in tardive-dyskinesia with va-
rying degree of success. 
Linnoila et al (1976) in a two week 
trial of Sodium Valproate in tardive dys-
kinesia reported significant improvement 
in 17 patients out of a total of 32 with 
oro-facial dyskinesia. Involuntary move-
ments of extremities and dystonic spasms 
were also significantly reduced in 7 out of 
9 patients. Gibson (1978) did not find any 
change in tardive dyskinesia in 25 schi-
zophrenic patients, given Sodium Valpro-
ate for one month. Casey annd Hammers-
tad (1979) and Crowe (1983) found it 
useful in tardive-dyskinesia. 
Various studies of drug trials in tar-
dive-dyskinesia suffer from a number of de-
ficiencies. These have been discussed in de-
tail by Jeste and Wyatt (1982). 
Despite considerable use of neurolep-
tics in our country and recognition that 
many of our patients have tardive dyski-
nesia, there is no report of any signific-
ance from our country regarding its ma-
nagement. Therefore, we studied the ef-
fect of Sodium Valproate on tardive-dys-
kinesia in psychiatric outpatients on long 
term antipsychotic therapy. An attempt 
was made to circumvent limitations of 
earlier studies. 
Material and Methods 
The patients having tardive dyskinesia 
diagnosed by two independent psychiatrists 
form the sample of study. It was ensured 
that each subject had received at least 100 
gms of Chlorpromazine equivalents of an-
tipsychotics in total and was on antipsy-
chotic therapy for atleast three months. Pa-
tients having any uncontrolled organic 
brain illness were excluded from the study. 
, Assessments of tardive-dyskinesia were 
made on Abbreviated Dyskinesia Scale 
(ADS) of Simpson et al (1979). 
A total of fifteen patients were found 
suitable for the study. Informed consent 
was taken from all the patients. All the sub-
jects were assessed on three subsequent oc-
casions over a period of one month to fur-
ther ensure the diagnosis. 
Sodium Valproate was given in tablet 
form in fixed dosage of 1200 mg/day (400 
mg t. i. d.) for four weeks. Assessments were 
fione at 0, 2 and 4 weeks of trial. Mainten-
ance medication of antipsychotics and anti-
parkinsonian agents was continued without 
any change in the dosage during trial pe-
riod. 
Results 
Sample consisted of fifteen subjects, 
twelve males and three females, with mean 
age of 37.67 years (S. D 1428 yrs). They R. CHADDA tc P. KULHARA  HI 
TABLE 
Scores on Abbreviated Dyskinesia Scale (ADS) after 0.2 and 4 weeks of treatment with Sodium Valproate 
Scores on ADS 
Patient 
No.  0 
week 
2" 
weeks 
4... 
weeks 
% reduction in 
scores after 
4 weeks. 
1* 
2* 
3* 
4* 
5' 
6' 
7 
8' 
9 
10* 
11 
12 
U 
14* 
15* 
17 
23 
11 
39 
30 
10 
33 
9 
26 
17 
24 
29 
13 
41 
21 
8 
17 
5 
27 
13 
4 
19 
5 
21 
11 
26 
8 
10 
18 
20 
6 
11 
3 
5 
12 
0 
23 
4 
18 
7 
14 
16 
7 
18 
8 
64.71 
52.17 
72 73 
87.79 
60.00 
100 00 
30.30 
55.55 
30.77 
58.82 
41.67 
44.83 
46.15 
56.98 
61.90 
MEAN  22.867 ±10.211  14.800 ±6.085  10.133 ±6.556  57.625 ±18.883 
• Patients, who showed more than 50% improvement 
" t "5.0603, p<,01 at df- 14 
••• t = 4.8308. p<.001 atdf-14 
had been on neuroleptic therapy for a dura-
tion varying from 11 months to 20 years 
(mean 8.195 yrs, S.D. 4.026 yrs). 
The Table shows scores of the pa-
tients on Abbreviated Dyskinesia Scale 
(ADS) at 0, 2 and 4 weeks and percentage 
improvement in tardive-dyskinesia after 4 
weeks of trial with Sodium Valproate. 
There was a significant improvement in 
tardive dyskinesia both after 2 and 4 weeks 
of trial ( P < .01 and < .001 at 2 and 
4 weeks respectively). 
Discussion 
Sodium Valproate was found effective 
in tardive-dyskinesia. Ten out of the fifteen 
patients showed more than 50% reduction 
in ADS ratings, while in one of the patients, 
complete remission of dyskinesia 
symptoms was achieved. 
In our study, we used relatively strict 
criteria for diagnosis of tardive dyskinesia 
(criteria as recommended by Jeste and 
Wyatt 1981). In addition, we made assess-
ments on ADS, which has been shown to 
have good reliability and validity (Simpson 
ct al 1979). The only limitation of our study 
is that ours is an open trial. But if we take 
Jeste and Waytt's (1982) suggestion of ta-
king a patient in an open trial as improved 
only if improvement is more than 50%, 
66.67% of our sample showed improve-
ment in 4 weeks. 
In earlier studies, Linnoila et al (1976), 
Casey and Hammerstad (1979) and Crowe 
(1983) found Sodium Valproate useful in 
tardive-dyskinesia, while Gibson (1978) 
failed to find any significant improvement 
in tardive-dyskinesia with Sodium Valpro-
ate in their sample. The main criticism 
against Gibson's study is that inadequate 
doses of Sodium Valproate (600 mg/day) 
was used and only clinical global assess-
ments of dyskinesia were made. 
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Oro-facial dyskinesia were totally or signi-
ficantly relieved with Sodium Valproate 
in dosage of 900 mg/day. No correlation 
was found between blood levels of valpro-
ate and improvement. However, Casey and 
Hammcrstad (1979) in a nine week trial on 
one patient found modest improvement in 
dosage of 900-2100 mg/d and a greater im-
provement with dosage above 2100 
mg/day and dyskinetic symptoms increased 
when blood levels of Valproate went below 
65 ^g/ml and decreased with levels above 
65 //g/ml. This suggests that a sustained mi-
mal blood level may be necessary for im-
provement. 
Crowe (1983) found improvement in 
dyskinesia with Sodium Valproate in dos-
age^ above 400 mg/day concurrently with 
existing neuroleptic treatments in 8 pa-
tients. In most cases, control of symptoms 
could be achieved within two weeks with 
the dose and could be maintained, provided 
dose was not altered. Patients were follo-
wed-up for a period of 2 'h years, while on 
Sodium valproate. 
Conclusion 
This open trial of Sodium Valproate, 
though limited in scope found Sodium Val-
proate quite effective in tardive dyskinesia. 
Our results suggest that it can be used along 
or concurrently with neuroleptics in tar-
dive dyskinesia. 
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